Treatment patterns and outcomes for locally advanced rectal cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how patients with locally advanced rectal cancer are treated and what their results are. It may help doctors understand which treatments work best for this stage of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older when you were diagnosed
- You have a confirmed diagnosis of rectal cancer (a biopsy showed cancer cells)
- Your cancer is stage II or III (it has grown into the rectum wall or nearby lymph nodes, but has not spread to distant organs)
- You did not have cancer that spread to other parts of the body at the time you were diagnosed
- You have not had another type of cancer diagnosed at the same time (not a double cancer)
- Your medical records are complete enough for the study team to review your treatment history
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a more customized treatment plan for people with locally advanced rectal (bowel) cancer after they receive FOLFIRINOX chemotherapy. It aims to reduce tumor spread risk and improve outcomes by tailoring the next steps based on scan details and your health status.
This trial tests whether adding two types of immunotherapy (cemiplimab with either fianlimab or REGN7075) to standard chemotherapy is safe and effective for people with locally advanced rectal cancer that has not been treated before. It may help shrink the tumor enough to allow surgery that preserves the ability to control bowel movements.
This trial studies giving long-course radiation and chemotherapy before surgery, plus an immunotherapy medicine (PD-1) to help the tumor shrink more. It’s for people with stage II or III rectal cancer that has not spread to distant organs.
This Phase 3 trial compares two chemotherapy combinations given with surgery for locally advanced rectal cancer. It aims to find out which approach works better and is safer for shrinking and controlling the cancer before or around the time of treatment.
This trial combines a special type of radiation (MRI-guided adaptive radiotherapy) with an immunotherapy drug (PD-1 antibody) and chemotherapy (CAPOX) for locally advanced rectal cancer. The goal is to see if this combination can improve treatment outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
Hear when a new Rectal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.